Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Tevogen Bio Inc CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares August 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares August 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health August 14, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities August 09, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback July 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian July 10, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities June 26, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility July 08, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances June 25, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference June 18, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Set to Join Russell 3000® Index June 12, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts June 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event June 07, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event June 06, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 June 06, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Reports First Quarter 2024 Financial Results May 29, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives May 16, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives May 10, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives May 01, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments April 26, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers April 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development April 03, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price March 28, 2024 From Tevogen Bio Inc Via GlobeNewswire Tickers TVGN TVGNW Tevogen Bio Announces Series A-1 Preferred Stock Investment March 27, 2024 From Tevogen Bio Inc Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.